Dashboard
1
Poor Management Efficiency with a low ROCE of 32.57%
- The company has been able to generate a Return on Capital Employed (avg) of 32.57% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 22.99% and Operating profit at 18.57% over the last 5 years
4
The company has declared Positive results for the last 5 consecutive quarters
5
With ROE of 10.61%, it has a very expensive valuation with a 4.83 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 31,294 Million (Large Cap)
45.00
NA
0.46%
-0.02
9.43%
4.04
Revenue and Profits:
Net Sales:
985 Million
(Quarterly Results - Jun 2026)
Net Profit:
236 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.8%
0%
-18.8%
6 Months
9.47%
0%
9.47%
1 Year
6.79%
0%
6.79%
2 Years
95.96%
0%
95.96%
3 Years
6.77%
0%
6.77%
4 Years
-28.99%
0%
-28.99%
5 Years
-13.78%
0%
-13.78%
iRay Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.99%
EBIT Growth (5y)
18.57%
EBIT to Interest (avg)
39.52
Debt to EBITDA (avg)
0.73
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
0.23
Tax Ratio
8.14%
Dividend Payout Ratio
22.29%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
17.04%
ROE (avg)
13.25%
Valuation key factors
Factor
Value
P/E Ratio
45
Industry P/E
Price to Book Value
4.83
EV to EBIT
51.62
EV to EBITDA
41.64
EV to Capital Employed
4.36
EV to Sales
13.10
PEG Ratio
7.71
Dividend Yield
0.46%
ROCE (Latest)
8.45%
ROE (Latest)
10.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
984.80
585.10
68.31%
Operating Profit (PBDIT) excl Other Income
374.00
219.50
70.39%
Interest
34.60
2.50
1,284.00%
Exceptional Items
-1.20
-5.60
78.57%
Consolidate Net Profit
235.70
189.40
24.45%
Operating Profit Margin (Excl OI)
263.00%
301.90%
-3.89%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 68.31% vs 9.32% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 24.45% vs 16.05% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,241.10
1,825.10
22.79%
Operating Profit (PBDIT) excl Other Income
786.60
487.70
61.29%
Interest
27.80
29.80
-6.71%
Exceptional Items
-11.40
-49.00
76.73%
Consolidate Net Profit
632.20
450.40
40.36%
Operating Profit Margin (Excl OI)
265.30%
216.30%
4.90%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 22.79% vs -1.71% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 40.36% vs -25.53% in Dec 2024
About iRay Technology Co., Ltd. 
iRay Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






